ArtemiC is a nutraceutical mouth spray that helps in recovering from severe COVID-19 symptoms
HempStreet has launched ‘ArtemiC’ a nutraceutical mouth spray to speed up recovery for patients with severe COVID-19 symptoms. ArtemiC has been launched in collaboration with MGC Pharma, a company with which HempStreet announced a partnership earlier this year. Headquartered in the UK, MGC Pharma is a pharmaceutical company working on polyherbal formulations based on cannabis and other phytopharmaceuticals.
HempStreet, through its collaboration with MGC Pharma, aims to create and bring to market phytopharma products to tackle mass ailments. With ArtemiC, the companies expect to reduce the symptoms of long COVID-19, which still affects more than 15 million people in India.
ArtemiC, includes four natural-based ingredients consisting of Curcumin, Boswellia serrata, Artemisinin and Vitamin C. ArtemiC Rescue and ArtemiC Support are the two variations of this product that will be available via medical practitioners and leading pharmacies. ArtemiC Rescue is an adjunctive treatment for the symptoms of COVID-19, whereas ArtemiC Support is a daily supplement that does not contain artemisinin. According to the double-blind, placebo-controlled clinical research findings, ArtemiC may minimise the severity of symptoms of COVID-19. In addition, the clinical trial demonstrated a significant reduction in one of the primary inflammatory markers related to COVID-19, C-reactive protein (CRP), an acute inflammatory protein that increases up to 1,000-fold at sites of infection or inflammation.
Abhishek Mohan, Founder and CEO, HempStreet, said, “HempStreet and MGC Pharma are committed to bringing thoroughly studied, incredibly effective, and ethically dispensed phytomedicines to treat widespread illnesses that affect people worldwide. An observational open-label controlled clinical trial of ArtemiC showed that the formulation demonstrated its efficacy in treating patients with severe COVID-19 for the first time. An estimated 15 million people in India are said to be suffering from “long covid” symptoms, making it a hidden mass ailment on its own. We look forward to helping patients nationwide with our products.”
Roby Zomer, MD and CEO, MGC Pharma, said, “Entry into significant global markets such as India is paramount to MGC Pharma’s strategy of advancing phytomedicine adoption globally. The latest observational trial results have expanded the possibilities for using ArtemiC in patients with severe COVID-19. In addition, working with HempStreet has facilitated access to our proprietary plant-inspired medicines for millions of people in India who are still affected by the symptoms of COVID-19. MGC Pharma has always placed the treatment of patients at the heart of everything we do, and these results are promising signs for those who the disease has most severely impacted.”